Lyon (France) and Cambridge (MA, US), April 5, 2024 – 6:00 p.m. CEST – PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135) biopharmaceutical company developing innovative treatments against severe and resistant bacterial infections
announces that it has filed with the Financial Markets Authority (AMF) in France its Universal Registration Document for the financial year ending December 31, 2023.
This document, including the annual financial report and the report of the Board of Directors on corporate governance, is accessible in the “Investors” section on the Company’s website (www.phaxiam.com) and on the website of the AMF (www.amf-france.org). It is also available at the Company’s head office (60 avenue Rockefeller, 69008 Lyon).
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company that develops innovative treatments against resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone represent more than two thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the regulated market of Euronext in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.
For more information, please visit: www.phaxiam.com
Contacts
|
PHAXIAM Eric Soyer COO & CFO +33 4 78 74 44 38 [email protected] |
NewCap Mathilde Bohin / Dušan Orešanský Investor Relations Arthur Rouille Media Relations +33 1 44 71 94 94 [email protected] |
Forecast information
This press release contains forward-looking statements, forecasts and estimates regarding the clinical programs, development plans, business and regulatory strategy and anticipated future performance of PHAXIAM and the market in which it operates. Some of these statements, forecasts and estimates may be identified by the use of words such as, without limitation, “believe”, “anticipate”, “expect”, “intend”, “plan”, “seek to”, “estimate”, “may”, “continue” and other similar expressions. All statements contained in this press release other than statements of historical fact are forward-looking statements. These statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were believed to be reasonable at the time they were made but which may or may not prove to be accurate. Actual events are difficult to predict and may depend on factors beyond PHAXIAM’s control. Therefore, actual results may differ materially from anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. The reader is invited to carefully read the risk factors appearing in the regulatory documents filed by the Company with the Financial Markets Authority (AMF), including in the 2023 Universal Registration Document of the Company filed with the AMF on April 5, 2024, as well as in future documents and reports filed by the Company. Given these uncertainties, no representation is made as to the accuracy or fairness of these forward-looking statements, forecasts and estimates. Further, forward-looking statements, forecasts and estimates speak only as of the date of this press release. PHAXIAM undertakes no obligation to update any such forward-looking statements, forecasts or estimates to reflect any change in PHAXIAM’s expectations with respect thereto, or any change in events, conditions or circumstances on which such statements, forecasts or estimates are based, except to the extent required by law
Attachment
20240405_CP_PHAXIAM_URD_FR